Sugi Predict

Sugi Predict / Compounds / SCHEMBL4916320

SCHEMBL4916320

SCHEMBL4916320

Cc1cccn1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.47
▸ HSP90AB1 P08238 1/20 0.47
▸ BCHE P06276 1/20 0.46
▸ BUB1 O43683 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ PIK3R1 P27986 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ TNK2 Q07912 1/20 0.38
▸ GPR119 Q8TDV5 3/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ ABCB1 P08183 1/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ESR2 Q92731 1/20 0.34
▸ STS P08842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163016 0.81 HSP90AA1 (0.47) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1
SCHEMBL15417736 0.81 HSP90AA1 (0.47) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1
SCHEMBL8264796 0.80 HSP90AA1 (0.46) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1
SCHEMBL13180192 0.80 HSP90AA1 (0.46) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1
SCHEMBL4076931 0.80 HSP90AA1 (0.46) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1
SCHEMBL24914436 0.80 HSP90AA1 (0.52) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1
SCHEMBL2616414 0.80 HSP90AA1 (0.46) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1
SCHEMBL7361304 0.80 HSP90AA1 (0.49) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1
SCHEMBL19204908 0.80 HSP90AA1 (0.46) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1
SCHEMBL8079706 0.79 HSP90AA1 (0.45) HSP90AA1HSP90AB1BCHEBUB1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117917406-A Heterocyclic compounds, process for their preparation and their use 四川科伦博泰生物医药股份有限公司 2024-04-23 — — CN disclosed
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 — — US disclosed
US-20220048902-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 — — US disclosed
WO-2019148044-A1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS EXELIXIS, INC. (US) 2019-08-01 — — WO disclosed
EP-3076959-B1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2018-07-04 — — EP disclosed
US-9845317-B2 Slow release of organoboronic acids in cross-coupling reactions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-12-19 — — US disclosed
EP-3013823-B1 IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF MERCK PATENT GMBH (DE) 2017-11-01 — — EP disclosed
US-20170298042-A1 VMAT INHIBITORY COMPOUNDS OREGON HEALTH & SCIENCE UNIVERSITY (US) 2017-10-19 — — US disclosed
US-9758509-B2 Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors ALLERGAN, INC. (US) 2017-09-12 — — US disclosed
CN-107001339-A Novel compounds 特殊治疗有限公司 2017-08-01 — — CN disclosed
CN-1052726-C 7-azabicyclo-[2,2,1]-heptane and-heptene derivatives as analgesics and anti-inflammatory agents UNIV VIRGINIA (US) 2000-05-24 — — CN disclosed
US-6060473-A 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands UCB S.A. - DTB (BE) 2000-05-09 — — US disclosed
EP-0778835-A4 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS UNIV VIRGINIA (US) 1999-02-03 — — EP disclosed
US-5817679-A ANALGESICS, ANTIINFLAMMATORY AGENTS UNIVERSITY OF VIRGINIA (US) 1998-10-06 — — US disclosed
CN-1163613-A 7-azabicyclo[2,2,1]-heptane and heptene derivatives as cholinergic receptor ligands UNIV VIRGINIA (US) 1997-10-29 — — CN disclosed
EP-0778835-A1 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS UNIVERSITY OF VIRGINIA (US) 1997-06-18 — — EP disclosed
CN-1133045-A 7-azabicyclo-[2,2,1]-heptane and-heptene derivatives as analgesics and anti-inflammatory agents UNIV VIRGINIA (US) 1996-10-09 — — CN disclosed
WO-1996006093-A1 7-AZABICYCLO[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS UNIVERSITY OF VIRGINIA (US) 1996-02-29 — — WO disclosed
EP-0691971-A1 7-AZABICYCLO- 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS UNIVERSITY OF VIRGINIA (US) 1996-01-17 — — EP disclosed
WO-1994022868-A1 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS UNIVERSITY OF VIRGINIA (US) 1994-10-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298042-A1 VMAT INHIBITORY COMPOUNDS SLC18A2, SLC18A3, SLC6A2 HSP90AA1 817/4885HSP90AB1 480/4885BCHE 1634/4885
US-20220048902-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 HSP90AA1 2009/4885HSP90AB1 1465/4885BCHE 4017/4885
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 HSP90AA1 2009/4885HSP90AB1 1465/4885BCHE 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.